Yeh Shan-Ju, Chen Shuo-Wei, Chen Bor-Sen
Laboratory of Automatic Control, Signaling Processing and Systems Biology, Department of Electrical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, United States.
Front Genet. 2020 Mar 6;11:117. doi: 10.3389/fgene.2020.00117. eCollection 2020.
Colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide. The mechanisms leading to the progression of CRC are involved in both genetic and epigenetic regulations. In this study, we applied systems biology methods to identify potential biomarkers and conduct drug discovery in a computational approach. Using big database mining, we constructed a candidate protein-protein interaction network and a candidate gene regulatory network, combining them into a genome-wide genetic and epigenetic network (GWGEN). With the assistance of system identification and model selection approaches, we obtain real GWGENs for early-stage, mid-stage, and late-stage CRC. Subsequently, we extracted core GWGENs for each stage of CRC from their real GWGENs through a principal network projection method, and projected them to the Kyoto Encyclopedia of Genes and Genomes pathways for further analysis. Finally, we compared these core pathways resulting in different molecular mechanisms in each stage of CRC and identified carcinogenic biomarkers for the design of multiple-molecule drugs to prevent the progression of CRC. Based on the identified gene expression signatures, we suggested potential compounds combined with known CRC drugs to prevent the progression of CRC with querying Connectivity Map (CMap).
结直肠癌(CRC)是全球第三大最常被诊断出的癌症类型。导致CRC进展的机制涉及遗传和表观遗传调控。在本研究中,我们应用系统生物学方法以计算方式识别潜在生物标志物并进行药物发现。通过挖掘大型数据库,我们构建了一个候选蛋白质 - 蛋白质相互作用网络和一个候选基因调控网络,并将它们合并成一个全基因组遗传和表观遗传网络(GWGEN)。借助系统识别和模型选择方法,我们获得了早期、中期和晚期CRC的真实GWGEN。随后,我们通过主网络投影方法从其真实GWGEN中提取每个CRC阶段的核心GWGEN,并将它们投影到京都基因与基因组百科全书通路进行进一步分析。最后,我们比较了这些在CRC各阶段导致不同分子机制的核心通路,并鉴定出致癌生物标志物,用于设计多分子药物以预防CRC进展。基于所识别的基因表达特征,我们通过查询连通性图谱(CMap)建议了与已知CRC药物联合使用的潜在化合物,以预防CRC进展。